{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042419","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.014909+00:00","generated_at":"2026-06-11T10:44:24.678161+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kodiak Sciences Q2 net loss $80.2M; winds down tarcocimab after Phase 3 DME miss","bullets":["Q2 2023 net loss $80.2M ($1.53/sh) vs $90.6M ($1.74/sh) in Q2 2022.","Cash and equivalents $378.7M at June 30, 2023.","Phase 3 GLEAM and GLIMMER in DME missed primary efficacy endpoint; tarcocimab studies being wound down.","Phase 3 DAYLIGHT in wet AMD met endpoint; no cataract imbalance observed.","KSI-501 Phase 1 enrollment completed; exploring both unconjugated protein and bioconjugate forms."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042419","json":"https://secwatch.observer/filing/0000950170-23-042419.json","markdown":"https://secwatch.observer/filing/0000950170-23-042419.md","text":"https://secwatch.observer/filing/0000950170-23-042419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/0000950170-23-042419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/kod-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:44:24.678161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55d5f5d268a2ecca15fefe247b27d18b2d4252fc","claim":"Kodiak Sciences Inc. reported the quarter ended June 30, 2023 results: net income $80.2 million, or $1.53 per share on both a basic and diluted basis, EPS $1.53 per share on both a basic and diluted basis.","evidence_excerpt":"The net loss for the second quarter of 2023 was $80.2 million, or $1.53 per share on both a basic and diluted basis","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/0000950170-23-042419-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"$80.2 million, or $1.53 per share on both a basic and diluted basis"},{"label":"EPS","value":"$1.53 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}